News | January 24, 2011

FDA Panel Recommends MRI Nervous System Imaging Agent

January 24, 2011 – A U.S. Food and Drug Administration’s (FDA) panel voted unanimously last week to recommend the clearance of a magnetic resonance imaging (MRI) contrast agent to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system (CNS).

The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee said clinical trial and postmarketing data for a gadobutrol injection, a macrocyclic 1.0 molar gadolinium-based contrast agent (GBCA), support approval of the product.

In addition to the vote for approval, committee members concurred in a 15-1 vote that gadobutrol should be labeled without an nephrogenic systemic fibrosis (NSF) contraindication in the at-risk population. NSF is a very rare but serious disease that affects a small percentage of patients with severe renal impairment who undergo contrast-enhanced MRI. All marketed GBCAs have a boxed warning about the potential for NSF in patients with chronic severe kidney disease or acute kidney injury.

Gadobutrol is formulated at a 1.0 molar concentration (mol/L), which provides a higher concentration (lower volume) compared to other contrast agents used for CNS imaging. Bayer HealthCare Pharmaceuticals Inc. said it will continue to work with the FDA as it finalizes its review of gadobutrol.

"Bayer is pleased that the advisory committee recognized the totality of the clinical and post-marketing data presented today," said Pamela A. Cyrus, M.D., vice president and head of U.S. medical affairs, Bayer HealthCare Pharmaceuticals. "If approved by the FDA, Bayer believes that gadobutrol will provide healthcare providers with an additional new option for CNS imaging in the United States."

Data presented at the advisory committee meeting included results from two adequate and well-controlled phase 3 studies that confirmed the efficacy and safety of gadobutrol injection in contrast-enhanced MRI of the CNS. Prospectively defined primary and secondary endpoints were met in the two studies. The first phase 3 study compared the efficacy of combined gadobutrol-enhanced images plus unenhanced images to unenhanced images alone. The second phase 3 study used a crossover design with an active control, gadoteridol, to also compare the efficacy of the combined gadobutrol-enhanced plus unenhanced images to unenhanced images alone, as well as to confirm noninferiority of combined gadobutrol imaging versus combined gadoteridol imaging.
The results of the first phase 3 study showed that gadobutrol-enhanced images compared to unenhanced images were superior in diagnostic performance and superior for the visualization variables, contrast enhancement, border delineation, and internal morphology. The results for comparison of unenhanced images compared to gadobutrol-enhanced images were consistent across both Phase 3 trials. In the second Phase 3 study comparing gadobutrol-enhanced images to images enhanced with the approved contrast agent gadoteridol, gadobutrol was confirmed to be non-inferior to gadoteridol with respect to visualization variables, contrast enhancement, border delineation and internal morphology, as well as the number of lesions detected.

The most common adverse drug reactions observed in phase 2-4 trials for gadobutrol were generally consistent with those of other gadolinium based contrast agents. Across the studies (n=4,549), the most common adverse events associated with gadobutrol were: headache (1.5%), nausea (1.2%), injection site reactions (0.6%), dysgeusia (0.5%), feeling hot (0.5%), dizziness (0.4%), vomiting (0.4%), rash (0.3%), pruritis (0.2%), erythema (0.2%), dyspnea (0.2%), parasthesia (0.1%). During the entire clinical development program of gadobutrol, only isolated reports of serious adverse events were recorded. Overall, serious AEs (including fatal) were observed in 17 (0.4%) of 4,549 patients. One of the 17 serious AEs reported in the gadobutrol group was considered drug-related by the investigator (crystals in urine one day after injection).

The New Drug Application (NDA) for gadobutrol was submitted to the FDA on May 14, 2010. The advisory committee's recommendations are not binding, but FDA reviewers will consider the panel's recommendation in its final assessment of the NDA.
For more information: www.bayer.com

Related Content

Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
High Prevalence of Atherosclerosis Found in Lower Risk Patients
News | Magnetic Resonance Imaging (MRI) | June 08, 2018
Whole-body magnetic resonance angiography (MRA) found a surprisingly high prevalence of atherosclerosis in people...
Philips Receives FDA 510(k) for Ingenia Elition MR System
Technology | Magnetic Resonance Imaging (MRI) | June 07, 2018
Philips announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its...
New Studies Highlight MRI Use for Prostate Cancer Screening and Management
News | Magnetic Resonance Imaging (MRI) | May 21, 2018
Three new studies presented at the 113th annual meeting of the American Urological Association (AUA) highlight the...
MRI "Glove" Provides New Look at Hand Anatomy

An experiment showed that a glove-shaped detector could yield images of bones, cartilage, and muscles interacting as a hand 'plays piano.' Traditionally, MRI had required patients to remain strictly motionless.Image courtesy of Nature Biomedical Engineering; Bei Zhang, Martijn Cloos, Daniel Sodickson

News | Magnetic Resonance Imaging (MRI) | May 17, 2018
A new kind of magnetic resonance imaging (MRI) component in the shape of a glove delivers the first clear images of...
FDA Clears Medic Vision's iQMR MRI Image Enhancement Technology

Image courtesy of Medic Vision Imaging Solutions

Technology | Magnetic Resonance Imaging (MRI) | May 15, 2018
May 15, 2018 — Medic Vision Imaging Solutions Ltd. announced that the U.S.
Impaired Brain Pathways May Cause Attention Problems After Stroke
News | Neuro Imaging | May 10, 2018
Damage to some of the pathways that carry information throughout the brain may be responsible for attention deficit in...
Overlay Init